OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $115,312.14 in Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average price of $1.71 per share, with a total value of $115,312.14. Following the transaction, the chief executive officer now owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. The trade was a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The stock was purchased at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was bought at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The shares were bought at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.56 per share, with a total value of $780,000.00.

OPKO Health Trading Up 8.9 %

Shares of OPKO Health stock traded up $0.16 on Tuesday, reaching $1.91. The company had a trading volume of 19,083,037 shares, compared to its average volume of 4,621,864. The firm's 50 day moving average price is $1.56 and its two-hundred day moving average price is $1.55. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.95. The firm has a market cap of $1.30 billion, a PE ratio of -10.08 and a beta of 1.63.

Remove Ads

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. Sell-side analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday. Barrington Research reiterated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday. Finally, StockNews.com raised OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday.

Institutional Trading of OPKO Health

Several hedge funds have recently made changes to their positions in OPK. FMR LLC grew its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in OPKO Health in the 3rd quarter valued at approximately $45,000. Cibc World Markets Corp acquired a new position in shares of OPKO Health in the fourth quarter worth $45,000. Zacks Investment Management purchased a new stake in shares of OPKO Health during the fourth quarter worth $49,000. Finally, Ieq Capital LLC acquired a new stake in shares of OPKO Health in the fourth quarter valued at $52,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.